You are here

US FDA warns Indian drugmaker Lupin on repeated quality violations

In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the firm chose to override the results. Lupin called the failed tests at the plant "laboratory error".


LUPIN Ltd, which makes generic antibiotics, antidepressants and heart medications for sale in the United States, was warned by the Food and Drug Administration (FDA) for repeatedly ignoring tests showing that pills made at two of its facilities didn't meet quality standards....

Market voices on: